Abivax stock climbed 3.0% to €104.2 on Euronext Paris today after Goldman Sachs opened coverage of the company’s American Depositary Shares with a Buy rating and a $155 price target. The investment bank cited the multibillion-euro revenue potential of the company’s lead oral therapy, obefazimod.
Goldman Sachs pointed to late-stage clinical data in ulcerative colitis as a factor that reduces the regulatory and commercial risk for the pill, noting the drug’s performance in that inflammatory bowel disease, which remains an area of high unmet medical need.
In its modeling, Goldman Sachs framed obefazimod as a "multiblockbuster" opportunity within inflammatory bowel disease, assigning a projected peak sales figure of 4 billion for ulcerative colitis based on efficacy similar to biologic treatments. The bank also identified further upside potential in Crohn's disease, estimating 3.5 billion in peak sales there and noting that mid-stage trial data are expected in mid-2027.
The Goldman Sachs initiation expanded an already unanimous group of bullish analysts: before this coverage start, Abivax had 11 Buy recommendations and no Hold or Sell ratings. That consensus reflects growing institutional confidence in obefazimod's commercial outlook, according to the reporting.
Adding to the supportive backdrop for the shares, Bank of America filed with France's securities regulator in early September that it had passed the 5% ownership threshold in Abivax, a disclosure signaling meaningful institutional accumulation and lending further support to the stock in recent trading sessions.
Investors are also positioning ahead of Abivax's next scheduled earnings release on September 21. The company’s most recent quarterly results exceeded consensus expectations by a notable margin, a factor that appears to be influencing current pre-earnings positioning.
The wider market environment was constructive during the session, with U.S. equities trading higher and helping to support risk appetite across global markets, including European clinical-stage biotechnology names. The S&P 500 added 0.2% while the Dow Jones Industrial Average gained 0.4%, providing a generally favorable macro tone that benefited Abivax and its sector peers.
Combined, the Goldman Sachs coverage initiation provided an immediate catalyst, while institutional buying, pre-earnings positioning and the positive market backdrop pushed Abivax to a session high of €105.1. The stock remains well below its 52-week high of €139, but the recent moves have kept it within reach of that level.
Context and market reaction
Goldman Sachs' valuation assumptions and sales forecasts for obefazimod are central to the bank’s Buy recommendation and $155 price target. The firm’s view rests on both the late-stage evidence in ulcerative colitis and the expectation of further trial results in Crohn's disease in mid-2027.
Institutional interest, exemplified by Bank of America’s disclosed stake, has reinforced the momentum generated by the analyst initiation. With an earnings date on the calendar, market participants appear to be positioning ahead of potential near-term news.
What to watch next
- The company’s earnings report on September 21, which may act as a further catalyst for the shares.
- Mid-2027 mid-stage Crohn's disease trial data for obefazimod, which Goldman Sachs views as an additional upside opportunity.
- Continued institutional accumulation or further analyst coverage changes that could affect sentiment toward the stock.